chf

CHF-4227 是一种新型高效且具有选择性的雌激素受体调节剂，可降低胆固醇合低密度脂蛋白胆固醇浓度。

CHF-5022 is a nonsteroidal anti-inflammatory drug that selectively inhibits the production of beta-amyloid protein (1-42) (ABETA42).

CHF-2060 is a novel acetylcholinesterase inhibitor.

CHF-2993 is a bio-active chemical.

CHF 1255 is a potential drug for the treatment of heart failure.

CH-5137291 is a pure AR antagonist with AR nuclear translocation inhibition activity. It inhibits castration and prevents the growth of prostate cancer cells.

CHF 2819 is a novel orally active acetylcholinesterase inhibitor (AChE) developed for the treatment of Alzheimer's disease (AD). CHF 2819 is a selective inhibitor of AChE, it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE).

CHF-6366是一种高效的M3毒蕈碱拮抗剂和β2肾上腺素能受体激动剂，具有pKi值分别为10.4和11.4。同时，CHF-6366作为一种弱钙离子通道抑制剂，其IC50约为50μM。该化合物能够抑制豚鼠的支气管收缩，适用于慢性阻塞性肺疾病研究。

CHF-6523是一种 PI3Kδ 抑制剂，可用于慢性阻塞性肺疾病（COPD）相关研究。

Nolomirole HCl（CHF 1035） 是一种具有口服活性的新型选择性多巴胺激动剂，对去甲肾上腺素的释放有抑制作用，可用于研究轻度慢性心力衰竭。

Indantadol HCl (CHF-3381) 是一种 NMDA 拮抗剂和非选择性 MAO 抑制剂。

Tanimilast (CHF-6001) 是一种新型的高效选择性磷酸二酯酶 4 抑制剂，IC 50值为0.026 ± 0.006 nM。Tanimilast 具有强大的抗炎活性，适用于肺部局部用药。Tanimilast 用于研究阻塞性肺病。

Nolomirole is a dopamine receptor agonist that reduces symptoms of congestive heart failure caused by monoclinine.

CHF5407（SVT-47060） 是一种具有有效性和选择性的毒蕈碱 M3 受体拮抗剂，可长期作用于毒蕈碱受体。CHF5407 对支气管痉挛有作用，可用于研究呼吸系统疾病。

Itanapraced (CHF5074) 是新型γ-secretase 调节剂，能够降低 Aβ42 (IC50=3.6 nM) 和 Aβ40 (IC50=18.4 nM) 分泌。

p38-α MAPK-IN-5 是一种有效的 p38α抑制剂，对 p38α、p38 β、p38γ、p38δ 的 IC50分别为 0.1 nM、0.2 nM、944 nM、4100 nM。p38-α MAPK-IN-5 具有抗炎作用，并且具有用于哮喘和慢性阻塞性肺病 (COPD) 研究的潜力。

FCHFHS-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity[1].

Quinapril-d5 is intended for use as an internal standard for the quantification of quinapril by GC- or LC-MS. Quinapril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor quinaprilat. In vivo, quinapril reduces mean arterial pressure in renal hypertensive and spontaneously hypertensive rats. It inhibits angiotensin I-induced pressor responses in normotensive rats and dogs. Quinapril prevents left ventricular heart failure in CHF 14.6 cardiomyopathic hamsters. Formulations containing quinapril have been used in the treatment of hypertension, heart failure, and diabetic nephropathy.

Nitrodenafil is a related compound of Sildenafil -- a phosphodiesterase inhibitor.

BMS-193884 is an oral endothelin antagonist for the treatment of congestive heart failure (CHF) and pulmonary arterial hypertension.

Trandolapril 是 Trandolaprilat 的前体药物。Trandolapril 是一种口服血管紧张素转换酶抑制剂，在高血压和充血性心力衰竭及心肌梗死领域有研究价值。

Ganstigmine is an acetylcholinesterase inhibitor for Alzheimer's disease.

Nebentan (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan . Nebentan inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively[1]. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo[2]. Nebentan inhibits the specific binding of [125I] endothelin-1 to endothelin ETA and ETB receptors in a concentration dependent manner,Ki values are 0.697 nM and 1.53 nM for human and rat endothelin ETA receptors, respectively. In contrast, YM598 exhibits low affinities for human and rat endothelin ETB receptors, with Ki values of 569 nM and 155 nM,respectively[1].In measurement of intracellular Ca2+ concentration, Nebentan concentration-dependently inhibits the increase in [Ca2+]i induced by 10 nM endothelin-1 in both CHO cells and A10 cells, the IC50 values are 26.2 nM for CHO cells and 26.7 nM for A10 cells, respectively[1]. Nebentan (oral administration; 0.1-1 mg kg; 4 weeks) significantly inhibits the progression of pulmonary hypertension and the development of right ventricular hypertrophy[2].Nebentan (oral administration; 1 mg kg; 30 weeks) significantly ameliorates the poor survival rate of CHF rats, it markedly reduces the hypertrophy of both ventricles as well as pulmonary congestion[2]. [1]. Hironori Yuyama, et al. Pharmacological Characterization of YM598, an Orally Active and Highly Potent Selective Endothelin ET(A) Receptor Antagonist. Eur J Pharmacol. 2003 Sep 30;478(1):61-71. [2]. Akira Fujimori, et al. YM598, an Orally Active ET(A) Receptor Antagonist, Ameliorates the Progression of Cardiopulmonary Changes and Both-Side Heart Failure in Rats With Cor Pulmonale and Myocardial Infarction. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S354-7.

ZEN-2759 是一种有效的 BET 小分子抑制剂，对 BRD4(BD1)、BRD4(BD2) 和 BRD4(BD1BD2) 有抑制作用。

FGF/PDGF/VEGF RTK Inhibitor is a potent, reversible, atp-competitive inhibitor against pdgfrβ, fgfr-1, and vegfr-2 (ic50 = 20, 90, and 240 nm, respectively) and effectively suppresses vegf-stimulated proliferation of hmvecs (ec50 = 420 nm).

Trandolapril D5 is a deuterium labeled Trandolapril. Trandolapril is an orally active inhibitor of angiotensin converting enzyme (ACE) for hypertension and congestive heart failure (CHF).

Candesartan (CV 11974) 是一种血管紧张素II 受体拮抗剂(IC50:0.26 nM)。